Alectinib is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan drug designation.
仅供研究使用。 我们不向患者出售。
名称 | Alectinib(CH5424802) |
---|---|
Iupac 化学名称 | 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile |
同义词 | Alectinib;CH5424802;CH-5424802;CH 5424802 |
英文同义词 | Alectinib;CH5424802;CH-5424802;CH 5424802 |
分子式 | C30H34N4O2 |
分子量 | 482.62 |
Smile | C(C)C1=CC2=C(C(C=3NC4=CC(=CC=C4C3C2=O)C#N)(C)C)C=C1N1CCC(CC1)N1CCOCC1 |
InChiKey | KDGFLJKFZUIJMX-UHFFFAOYSA-N |
InChi | InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3 |
Cas号 | 1256580-46-7 |
相关CAS号 |
包装 | 价格 | 库存 | 纯度 | 备货期 |
---|---|---|---|---|
大货 | 询价 | 询价 | 询价 |